FY2024 EPS Estimate for Zevra Therapeutics Raised by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for Zevra Therapeutics in a research report issued to clients and investors on Wednesday, January 8th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of ($1.93) for the year, up from their previous estimate of ($1.97). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.96) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. During the same period last year, the company earned ($0.40) EPS.

Several other research analysts have also recently weighed in on ZVRA. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Maxim Group raised their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. JMP Securities began coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Roth Mkm raised their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Finally, Guggenheim initiated coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target for the company. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA opened at $8.11 on Friday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock’s 50 day moving average price is $8.78 and its two-hundred day moving average price is $7.62. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The firm has a market capitalization of $432.88 million, a price-to-earnings ratio of -4.12 and a beta of 2.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC boosted its position in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after buying an additional 5,940 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares during the period. Hunter Associates Investment Management LLC bought a new stake in shares of Zevra Therapeutics in the third quarter worth $92,000. XTX Topco Ltd acquired a new stake in Zevra Therapeutics in the third quarter valued at $94,000. Finally, Intech Investment Management LLC bought a new position in Zevra Therapeutics during the 3rd quarter worth $95,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.